BOBULSKY SUSAN sold $75K of ADPT
BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 3,000 shares of Adaptive Biotechnologies Corp (ADPT) at $25.00 on 2026-08-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale: 3,000 shares at $25.00 on 2026-08-10 by the Chief Commercial Officer (MRD), with holdings after the sale of 396,989 shares and a stated 10b5-1 plan.
Market read
This is a routine insider sale filing with limited incremental information for trading decisions.
What to watch
Traders may over-weight insider sales; without additional context (e.g., total planned volume, prior sales cadence, or concurrent company news), the signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).
Ticker impact
Adaptive Biotechnologies insider BOBULSKY SUSAN sold 3,000 shares at $25.00 on 2026-08-10 under a 10b5-1 plan, totaling $75,000.
Likely minimal to modest, short-lived sentiment impact; no clear directional fundamental catalyst from the filing alone.
The disclosure is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling. The article provides sale size and price but no accompanying operational or financial update.
Market effects
No direct sector read-through; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so the market reaction should be muted.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider sale disclosure.
- insiderBOBULSKY SUSAN
Chief Commercial Officer (MRD) who sold shares under a 10b5-1 plan.